HOSPITAL UNIVERSITARIO RUBER
Departamento
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (35)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659
-
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4123-4130
-
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 2060-2069
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
2023
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499
2022
-
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*
British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969
-
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
eBioMedicine, Vol. 75
-
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
Future oncology (London, England), Vol. 18, Núm. 33, pp. 3677-3688
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review
Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257
-
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer
European Journal of Cancer, Vol. 148, pp. 134-145
-
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
npj Precision Oncology, Vol. 5, Núm. 1
-
Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3116-3125
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
EBioMedicine, Vol. 69
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
-
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
npj Breast Cancer, Vol. 7, Núm. 1
-
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1875, Núm. 1